about our company
PUTTING PVI CONTROL IN A WHOLE NEW LIGHT
At CardioFocus, we specialize in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation.
Our focused dedication on advancing cardiac ablation treatments has resulted in the ground-breaking HeartLight® Endoscopic Ablation System, integrating important new features into a never-before-seen platform as advanced as it is intuitive. And our ongoing research is taking laser ablation therapies to exciting new places.
THE HEARTLIGHT ENDOSCOPIC ABLATION SYSTEM
MAKING PVI CONTROL MORE ACCESSIBLE THAN EVER
The HeartLight Endoscopic Ablation System provides physicians with a number of unique and valuable new capabilities. Now, they can directly visualize anatomies intra-procedure, precisely target the application of laser energy, and deliver durable pulmonary vein isolation.
Aug 29 – Sept 2, 2020
BURKE BARRETTChief Executive Officer & President
MARK CASEYVP, Operations
IAN CHRISTIANSONVP, Regulatory Affairs & Quality Assurance
SCOTT FLETCHERVP, Finance & Administration
STUART JAMESONVP, International
SCOT MACDONELLVP, US Commercial
JERRY MELSKYVP, Engineering
LISA HAUSMANNSenior Director, Clinical Affairs
BOARD OF DIRECTORS
Mr. LaViolette serves as Chairman of the Board of Directors at CardioFocus.
He is the Managing Partner and Chief Operating Officer at SV Health Investors, bringing more than 35 years of global medical technology management experience. Previously, he served as the Chief Operating Officer of Boston Scientific Corporation (BSC), an $8 billion medical device leader. During his 15 years at BSC, he also held positions including: Group President Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International during a period in which revenues grew 20 times. Mr. LaViolette integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations. He previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Covidien).
Omar Amirana, MD
Dr. Amirana leads the strategic direction and development of the Life Sciences portfolio for Allied Minds (LSE: ALM.L), a publicly traded company focused on venture creation and commercialization. In addition to serving as CEO of two Allied Minds portfolio companies, he also contributes to the Allied Minds joint ventures with Bristol-Myers Squibb and General Electric. Dr. Amirana previously served as Partner at Oxford Bioscience Partners, a Boston-based venture capital firm with ~$1B under management. There he led the Series A investment in nFocus Neuromedical (brain aneurysm therapy; acquired by Covidien), served on numerous boards and participated in numerous financings. He has also served on the board of the Ignition Awards Committee at BU and the Coulter Committee at Columbia University. He has co-founded or held varying senior executive roles in four startups and served as VP of Business Development at St Jude Medical (now Abbott; NYSE:ABT).
Mr. Barrett joined CardioFocus in 2002 and currently serves as Chief Executive Officer (CEO), leveraging over 30 years of medical device industry experience into the role of CEO. He joined CardioFocus in 2002, and during his more than 15 years with the company has held roles of increasing responsibility from Vice President through to President and COO.
Prior to joining CardioFocus, Mr. Barrett was Vice President of Clinical Operations at Cyberkinetics Neurotechnology Systems, Inc., a public medical device company that achieved first-in-man success in novel, implantable brain-computer interfaces. He also served at Cyberonics as the Vice President, Business and Technology Development. Previously, Mr. Barrett held positions in business development, clinical & regulatory affairs, and quality auditing at Biofield Corporation, Dornier Medical Systems, and Bausch & Lomb.
Mr. Barrett is a co-inventor on numerous issued and pending patent applications. From 2010-2013 he served as the industry representative on the Food and Drug Administration’s (FDA) Circulatory Systems Device Advisory Panel. He received bachelor’s degrees in chemical engineering and chemistry from Syracuse University and a Master of Business Administration from Kennesaw University in Atlanta.
Mr. Larsen is a co-founder and Managing Director of Accuitive Medical Ventures. He brings over 35 years of operating experience, as well as expansive technical understanding and experience in the medical device industry. Mr. Larsen was a co-founder of Novoste Corporation with Tom Weldon where his efforts as a director and executive were critical to its ultimate success. Mr. Larsen also co-founded The Innovation Factory and serves as its Vice Chairman. Through his role at The Innovation Factory, Mr. Larsen has co-founded numerous companies including: Acufocus, AqueSys, Halscion, LipoSonix, Neuronetics and Sebacia. He holds over 30 issued U.S. and international patents on medical devices.
Bruce Robertson, PhD
As Managing Director of H.I.G. BioHealth Partners, Dr. Robertson focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Dr. Robertson has been active in the life sciences sector for more than 20 years. Prior to joining H.I.G., he served most recently as Managing Director at Toucan Capital, a venture capital fund focusing on life science investments. While at Toucan, Dr. Robertson invested in leading drug and device companies throughout the U.S. Prior to Toucan, he was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his private equity career, Dr. Robertson was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies.
Mr. Wethington serves as the President and Chief Executive Officer of Stimdia Medical, Inc, a privately-held company which is developing products to treat patients with ventilator induced diaphragmatic dysfunction (“VIDD”). He was previously the Chief Executive Officer and President of CardioInsight Technologies Inc. (acquired by Medtronic) as well as the Chief Executive Officer and President of Hemosphere, Inc. (acquired by CryoLife). Mr. Wethington has more than 25 years of cross functional medical device experience in the cardiovascular industry, including leadership roles at Guidant, Endocardial Solutions (acquired by St. Jude Medical), St. Jude Medical Inc. and CHF Solutions, Inc. (acquired by Gambro).
Accuitive Medical Ventures
Accuitive Medical Ventures is a venture capital firm with committed capital of $230 million. A market-driven firm looking for revolutionary medical device technology investment opportunities, Accuitive has offices in Atlanta, GA and Amelia Island, FL.
Aurora Funds is a family of venture capital funds committed to providing resources to help early stage healthcare and information technology companies reach their full potential. Aurora’s investment team has the experience, strategic relationships and capital to help companies accelerate their growth and gain a strong competitive advantage in their market space. Since its founding in 1994, Aurora has invested in over 60 portfolio companies, resulting in five IPOs and eight M&A transactions.
BioMed Ventures is the strategic investment arm of BioMed Realty. Acquired by Blackstone in 2016, BioMed Realty is the leading provider of real estate solutions to the life science industry – providing leasing, development, construction, redevelopment, acquisition, financing and property management to clients in the United States and United Kingdom, with over 12 million square feet of rentable space worldwide.
Fletcher Spaght Ventures
Fletcher Spaght Ventures, (FSV) is a balanced-stage venture capital firm investing in high growth opportunities in healthcare/life sciences and related information technology companies. FSV was established in 2001 by Fletcher Spaght, Inc. (FSI), a strategy consulting firm founded in 1983. The FSI:FSV collaboration provides key differentiation from other venture capital firms and allows for significant advantages in deal sourcing and investing.
HIG BioHealth Partners
With $400 million in assets under management, H.I.G. BioHealth Partners invests in a broad range of healthcare companies across multiple sectors and stages of development. Its seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. It invests in companies developing novel products for significant unmet medical needs.
Kestrel Management invests in early stage healthcare companies. Investments other than CardioFocus include Health Dialog (disease management), PHT Corp. (Clinical trial support), Iora Healthcare (patient centric primary care), and Constant Therapy (digital solutions to brain injury). Kestrel typically invests at the pre-revenue stage and partners with both angels and venture capital firms.
Sightline Partners is an alternative investment manager providing custom equity financing for differentiated, growth-stage healthcare companies. It invests in select, high-potential healthcare companies to unlock value others can’t. Through custom financing solutions and active management, Sightline Partners helps propel these companies to the exit and realize consistent performance for its investors.
SV Health Investors
SV Health Investors is a leading healthcare and life sciences venture capital and growth equity firm. Its goal is to transform healthcare – one investment at a time – by supporting the entrepreneurs who create and build breakthrough companies and treatments. With over $2 billion in capital under management in seven private healthcare funds, a 20-year track record in the US and Europe and offices in Boston, San Francisco and London, SV Health Investors drives game-changing innovation.
There are presently no open positions.